Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004).
Abstract: To determine outcome associated with cutaneous tumors treated via intratumoral chemotherapy with cisplatin and identify risk factors affecting local tumor control and complications in equidae. Methods: Retrospective case series. Methods: 573 equidae with 630 cutaneous tumors. Methods: Medical records of horses, mules, donkeys, and ponies with cutaneous tumors treated via intratumoral chemotherapy with cisplatin were analyzed. Results: 549 horses, 13 mules, 8 donkeys, and 3 ponies with 630 histologically confirmed cutaneous tumors were included. Tumors included sarcoids (n = 409), squamous cell carcinomas (151), soft tissue sarcomas (28), cutaneous lymphomas (26), and melanomas (16). Overall cure rate, defined as local control at 4 years, was 93.3%. For all tumor stages combined, cure rates after 1 course of treatment were 96.3% for sarcoids, 96% for lymphomas, 88% for squamous cell carcinomas, 85% for soft tissue sarcomas, and 81% for melanomas. Treatment protocol, tumor stage, and prior treatment were significant prognostic factors for tumor control. Treatment efficacy was lower for large tumors, those with gross postoperative residual disease, and those that had been treated previously with other modalities. Treatment was well tolerated. Local reactions were more likely to occur and to be more severe after the third and fourth treatment sessions. Conclusions: Results confirmed the value of intratumoral chemotherapy with cisplatin for treatment of cutaneous tumors in equidae. The results cannot be extrapolated to other formulations of cisplatin or other protocols that might be used.
Publication Date: 2007-05-17 PubMed ID: 17504043DOI: 10.2460/javma.230.10.1506Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research studies the outcomes and potential risk factors of treating cutaneous tumors on horses, mules, donkeys, and ponies with intratumoral chemotherapy using cisplatin. Results reveal a high cure rate and confirm the efficacy of this treatment methodology.
Overview of the Research
- This retrospective case series aimed to determine the long-term outcome and potential risk factors impacting local tumor control and complications in equidae, specifically following intratumoral chemotherapy treatment with cisplatin.
- The study focused on 573 equidae, including horses, mules, donkeys, and ponies with 630 confirmed cutaneous tumors.
- Tumors analyzed comprised sarcoids, squamous cell carcinomas, soft tissue sarcomas, cutaneous lymphomas, and melanomas.
Research Findings
- The overall cure rate, defined as local control at the conclusion of a 4-year period, was 93.3%.
- When considering all tumor stages, cure rates after a single course of treatment ranged from 81% for melanomas to 96.3% for sarcoids.
- Several factors emerged as significant indicators for tumor control, such as the treatment protocol, tumor stage, and any prior treatment received.
- Lower efficacy was noted for large tumors, those with observable postoperative residual disease, and tumors that had previously undergone other treatment methodologies.
- The treatment was generally well-tolerated, with local reactions more likely, and often more severe, after the third and fourth treatment sessions.
Conclusion of the Research
- The findings highlight the effectiveness of using intratumoral chemotherapy with cisplatin for treating cutaneous tumors in equidae, indicating a high cure rate with acceptable side effects.
- It is important, however, to note that these results cannot be extended to other formulations of cisplatin or other treatment protocols that may be utilized.
Cite This Article
APA
Théon AP, Wilson WD, Magdesian KG, Pusterla N, Snyder JR, Galuppo LD.
(2007).
Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004).
J Am Vet Med Assoc, 230(10), 1506-1513.
https://doi.org/10.2460/javma.230.10.1506 Publication
Researcher Affiliations
- Department of Surgery, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
MeSH Terms
- Animals
- Antineoplastic Agents / therapeutic use
- Carcinoma, Squamous Cell / drug therapy
- Carcinoma, Squamous Cell / mortality
- Carcinoma, Squamous Cell / veterinary
- Cisplatin / therapeutic use
- Equidae
- Female
- Horse Diseases / drug therapy
- Horses
- Male
- Melanoma / drug therapy
- Melanoma / mortality
- Melanoma / veterinary
- Neoplasm Staging / veterinary
- Retrospective Studies
- Sarcoma / drug therapy
- Sarcoma / mortality
- Sarcoma / veterinary
- Skin Neoplasms / drug therapy
- Skin Neoplasms / mortality
- Skin Neoplasms / veterinary
- Survival Analysis
- Treatment Outcome
Citations
This article has been cited 19 times.- Pimenta J, Cotovio M. Equine Veterinarian Perspectives on Mucocutaneous Tumors in Horses: A Survey-Based Study in Portugal. Animals (Basel) 2025 Jun 23;15(13).
- Lai N, Langova V, Thomas P, Nguyen S, Todd J, Herbert J, Blaxill JE. Evaluation of a Novel Cisplatin Poloxamer Gel Formulation in the Treatment of Incompletely Excised Soft-Tissue Sarcomas: 42 Dogs. Vet Sci 2025 Feb 27;12(3).
- Labens R, Saba C, Williams J, Hollis A, Ensink J, Jose-Cunilleras E, Jordana-Garcia M, Bergvall K, Ruppin M, Condon F, Spelta C, Elce Y, De Ridder T, Morton J, McGee C, Reddell P. Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas. Equine Vet J 2026 Jan;58(1):89-104.
- Bulnes F, Argüelles D, Buzón A, García-Álamo K, Rodríguez-Gómez IM, Hernández E, Mozos E. Concomitant melanoma and keratoma affecting the equine digit: clinical, pathological, and long-term follow-up findings. BMC Vet Res 2024 Oct 1;20(1):444.
- Zscherpe P, Kalbitz J, Weber LA, Paschke R, Mäder K, von Rechenberg B, Cavalleri JV, Meißner J, Klein K. Potent drug delivery enhancement of betulinic acid and NVX-207 into equine skin in vitro - a comparison between a novel oxygen flow-assisted transdermal application device and microemulsion gels. BMC Vet Res 2024 May 16;20(1):202.
- Fesmire CC, Peal B, Ruff J, Moyer E, McParland TJ, Derks K, O'Neil E, Emke C, Johnson B, Ghosh S, Petrella RA, DeWitt MR, Prange T, Fogle C, Sano MB. Investigation of integrated time nanosecond pulse irreversible electroporation against spontaneous equine melanoma. Front Vet Sci 2024;11:1232650.
- Pimenta J, Prada J, Pires I, Cotovio M. Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors. Animals (Basel) 2023 Dec 22;14(1).
- Risselada M, Worth DB. Review of local extravascular delivery systems for chemotherapeutic agents in small animals and horses. Can Vet J 2023 Oct;64(10):957-967.
- Pimenta J, Prada J, Cotovio M. Equine Melanocytic Tumors: A Narrative Review. Animals (Basel) 2023 Jan 10;13(2).
- Yi Z, Gao Y, Yu F, Zhu Y, Liu H, Li J, Murua Escobar H. Interventions for treatment of cutaneous melanoma in horses: a structured literature review. Vet Res Commun 2023 Jun;47(2):347-360.
- Weber LA, Delarocque J, Feige K, Kietzmann M, Kalbitz J, Meißner J, Paschke R, Cavalleri JV. Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses. Animals (Basel) 2021 Nov 13;11(11).
- Weber LA, Funtan A, Paschke R, Delarocque J, Kalbitz J, Meißner J, Feige K, Kietzmann M, Cavalleri JV. In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer. PLoS One 2020;15(11):e0241448.
- Billi T, Karadima V, Tyrnenopoulou P, Apostolopoulou EP, Brellou GD, Diakakis N. Surgical excision of a malignant metastatic melanoma located in a skeletal muscle of the lateral thorax of a horse. Vet Med Sci 2021 Mar;7(2):297-302.
- Weber LA, Meißner J, Delarocque J, Kalbitz J, Feige K, Kietzmann M, Michaelis A, Paschke R, Michael J, Pratscher B, Cavalleri JV. Betulinic acid shows anticancer activity against equine melanoma cells and permeates isolated equine skin in vitro. BMC Vet Res 2020 Feb 5;16(1):44.
- Worley DR, Hansen RJ, Wittenburg LA, Chubb LS, Gustafson DL. Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats. Anticancer Res 2016 Oct;36(10):5071-5078.
- Rothacker CC, Boyle AG, Levine DG. Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009-2014). Can Vet J 2015 Jul;56(7):709-14.
- Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM. Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. BMC Vet Res 2015 Jun 11;11:132.
- Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM. Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. BMC Vet Res 2015 May 14;11:107.
- Metcalfe LV, O'Brien PJ, Papakonstantinou S, Cahalan SD, McAllister H, Duggan VE. Malignant melanoma in a grey horse: case presentation and review of equine melanoma treatment options. Ir Vet J 2013 Nov 6;66(1):22.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
